AstraZeneca's Tezepelumab Succeeds in Phase III CROSSING Trial for Eosinophilic Esophagitis
Start here
AstraZeneca China has announced positive results from the Phase III CROSSING trial of Taiseido (tezepelumab) in eosinophilic esophagitis. Compared with placebo, patients achieved statistically significant and clinically meaningful histologic remission and symptom improvement at week 24, with efficacy sustained to week 52. At week 52, tezepelumab also achieved statistically significant complete endoscopic remission and eliminated endoscopically visible signs of inflammation and fibrosis. The results position tezepelumab as a potential treatment option for eosinophilic esophagitis, though full trial data, regulatory filings, and approval decisions remain ahead.
Written by a model from the reports · updated 3 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- WeChatAstraZeneca's Tezepelumab Posts Positive Phase III CROSSING Results in Eosinophilic Esophagitis
AstraZeneca China announced positive results from the Phase III CROSSING trial of Taiseido (tezepelumab) in eosinophilic esophagitis. Compared with placebo, patients achieved statistically significant and clinically meaningful histologic remission and symptom improvement at week 24, with efficacy sustained to week 52; at week 52, tezepelumab achieved statistically significant complete endoscopic remission and eliminated endoscopically visible signs of inflammation and fibrosis.
Coverage and heat for this story
Reports so far 1·Heat now 9·Peak heat 10 (Oct 21 10:00)·Reports, 24h +1
Two panels, same clock (pointer stays in sync): top is cumulative editorial reports — only rises; last point = All reports; slope = new reports that hour. Bottom is Live-board heatIndex — 7-day participants with a 24-hour half-life, so it can fall when talk cools.